← Elevance Health overview

Elevance Health vs Centene: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Elevance Health Inc (ELV)

Q3 2026
▼3▲1

Elevance beats Q2, raises guidance, but Medicaid losses and member drop weigh

  • Q2 earnings beat and raised 2026 guidance Elevance beat Q2 earnings and raised its 2026 profit outlook to at least $27 per share, backed by $4.3 billion in quarterly operating cash flow, buybacks, and dividends.

    This is the main positive event that drove the stock during the period.

  • Medicaid margins turn negative, prompting market exits Medicaid margins turned negative at -1.75%, forcing Elevance to exit some markets. This raises concerns about profitability in government programs and pressures the stock.

    This is a key negative development that hurt investor sentiment.

  • Suing CMS over $115M in lost Medicare Advantage bonuses Elevance is suing CMS over $115 million in lost Medicare Advantage bonuses. The lawsuit adds regulatory uncertainty and could affect future earnings if not resolved favorably.

    This new legal action is a notable negative factor for the stock.

  • Q3 earnings expected down ~30% year-over-year, stock falls 7.4% Q3 earnings are expected to drop about 30% from a year ago, and the stock fell 7.4% despite a $49.83 billion revenue beat. The company also lost 469,000 members.

    This captures the market's negative reaction and the member loss, which are new developments.

August 2026
▼2▲1

Elevance's 2026 profit squeeze may be bottoming as 2027 recovery bets build

  • 2026 earnings forecast cut, but stock already ran Analysts now expect Elevance to earn $6.18 a share this quarter, down about 30% from a year ago, with revenue forecasts also slipping. That is the near-term drag. But the stock had already climbed 33.6% in 90 days, so much of the bad news may be priced in.

    This is the core reason the stock is under pressure: falling profit expectations for 2026.

  • Margins seen bottoming in 2026, recovery in 2027 Greenskeeper Asset Management says Elevance's operating margins may have hit bottom this year. Medical cost inflation is stabilizing, government payment updates are better than feared, and the company is repricing plans to match costs. That sets up an earnings rebound in 2027, which is why long-term investors are looking past this year's weak profit.

    This explains the bull case: the profit downturn is temporary and a recovery is coming next year.

  • Industry cost trends split: some relief, some pressure UnitedHealth's medical costs fell sharply, helping its earnings and lifting the whole managed-care group. But CVS Health warned that its medical costs remain high, which dragged Elevance and peers down. Elevance's own cost ratio rose slightly, yet it still raised its 2026 profit guidance to at least $27 a share. The picture is uneven.

    Shows the tug-of-war on medical costs that directly drives Elevance's profit and stock price.

  • Lost 469,000 members even as revenue beat Elevance beat revenue expectations with $49.83 billion, but lost 469,000 customers and the stock fell 7.4%. Losing members shrinks the base of people paying premiums, which matters more for future growth than a one-quarter revenue beat. Investors focused on the membership decline.

    Membership loss is a concrete negative that pressures future revenue and the stock.

Latest
▼2▲1

Elevance's 2026 profit squeeze may be bottoming as 2027 recovery bets build

  • 2026 earnings forecast cut, but stock already ran Analysts now expect Elevance to earn $6.18 a share this quarter, down about 30% from a year ago, with revenue forecasts also slipping. That is the near-term drag. But the stock had already climbed 33.6% in 90 days, so much of the bad news may be priced in.

    This is the core reason the stock is under pressure: falling profit expectations for 2026.

  • Margins seen bottoming in 2026, recovery in 2027 Greenskeeper Asset Management says Elevance's operating margins may have hit bottom this year. Medical cost inflation is stabilizing, government payment updates are better than feared, and the company is repricing plans to match costs. That sets up an earnings rebound in 2027, which is why long-term investors are looking past this year's weak profit.

    This explains the bull case: the profit downturn is temporary and a recovery is coming next year.

  • Industry cost trends split: some relief, some pressure UnitedHealth's medical costs fell sharply, helping its earnings and lifting the whole managed-care group. But CVS Health warned that its medical costs remain high, which dragged Elevance and peers down. Elevance's own cost ratio rose slightly, yet it still raised its 2026 profit guidance to at least $27 a share. The picture is uneven.

    Shows the tug-of-war on medical costs that directly drives Elevance's profit and stock price.

  • Lost 469,000 members even as revenue beat Elevance beat revenue expectations with $49.83 billion, but lost 469,000 customers and the stock fell 7.4%. Losing members shrinks the base of people paying premiums, which matters more for future growth than a one-quarter revenue beat. Investors focused on the membership decline.

    Membership loss is a concrete negative that pressures future revenue and the stock.

July 2026
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

Q2 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

June 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

Centene Corp (CNC)

Q3 2026
▲2▼2

Centene's profit rebound overshadowed by Medicare Advantage retreat

  • Q2 earnings blowout and guidance hike Centene's Q2 adjusted EPS of $2.51 crushed the $1.09 consensus, and full-year 2026 guidance jumped to over $4.80 from $3.40. This shows a sharp turnaround in profitability, boosting investor confidence.

    This is the core positive event that drove the stock in Q3, directly answering what moved the price.

  • Medical cost stabilization and margin recovery The medical loss ratio improved to 89.6%, medical costs stabilized, and Marketplace margins recovered, lifting the pretax margin outlook to 4.5–5%. Medicaid rate increases of about 5% also cushion cost trends.

    This explains the operational improvements behind the profit beat and higher guidance, key drivers of the stock's positive move.

  • Medicare Part D subsidy elimination The Trump administration ended a $3.6 billion Medicare Part D subsidy, likely raising 2027 premiums and pressuring Centene's membership and payments. This creates a headwind for future revenue and profitability.

    This is a new regulatory risk that emerged in Q3 and weighs on the stock, providing a fair counterweight to the positive drivers.

  • Medicare Advantage county and state exits Centene is exiting 344 counties and three states in Medicare Advantage for 2027 amid CMS premium pressure and rising costs, reducing future revenue and adding uncertainty despite the broader profit recovery.

    This strategic retreat signals challenges in a key segment and tempers the positive earnings news, directly impacting the stock's outlook.

September 2026
▲3▼1

Centene's Profit Recovery and Guidance Hikes Offset Medicare Advantage Pullback

  • Marketplace Turnaround Boosts Profit Outlook Centene's Marketplace business is recovering, with margins improving and the company raising its 2026 pretax margin outlook to 4.5-5% from 3%. This shift toward profitability over volume is lifting investor confidence and the stock price.

    This is a key driver of the improved earnings outlook and directly explains the positive price movement.

  • Guidance Raised on Strong Fundamentals Centene raised its 2026 revenue and adjusted EPS guidance, now expecting EPS to exceed $4.80 versus the prior $3.40. This reflects confidence in its business and is a major positive catalyst for the stock.

    The guidance increase is a direct and significant positive driver for the stock price.

  • Q2 Profit Recovery and Medicaid Rate Increase Centene posted a Q2 profit recovery with adjusted EPS of $2.51 versus a year-ago loss and reaffirmed 2026 EPS guidance above $4.80. It also raised its expected 2026 Medicaid rate increase to about 5%, cushioning medical-cost trends.

    The profit recovery and rate increase are fundamental positives that support the stock's upward movement.

  • Medicare Advantage Pullback Adds Uncertainty Centene is exiting 344 counties and three states for 2027 Medicare Advantage, as CMS premium pressure and rising costs force a retrenchment. This reduces future membership and revenue, weighing on the stock.

    This is a new negative development that could pressure the stock by limiting growth prospects.

Latest
▲3▼1

Centene's Profit Recovery and Guidance Hikes Offset Medicare Advantage Pullback

  • Marketplace Turnaround Boosts Profit Outlook Centene's Marketplace business is recovering, with margins improving and the company raising its 2026 pretax margin outlook to 4.5-5% from 3%. This shift toward profitability over volume is lifting investor confidence and the stock price.

    This is a key driver of the improved earnings outlook and directly explains the positive price movement.

  • Guidance Raised on Strong Fundamentals Centene raised its 2026 revenue and adjusted EPS guidance, now expecting EPS to exceed $4.80 versus the prior $3.40. This reflects confidence in its business and is a major positive catalyst for the stock.

    The guidance increase is a direct and significant positive driver for the stock price.

  • Q2 Profit Recovery and Medicaid Rate Increase Centene posted a Q2 profit recovery with adjusted EPS of $2.51 versus a year-ago loss and reaffirmed 2026 EPS guidance above $4.80. It also raised its expected 2026 Medicaid rate increase to about 5%, cushioning medical-cost trends.

    The profit recovery and rate increase are fundamental positives that support the stock's upward movement.

  • Medicare Advantage Pullback Adds Uncertainty Centene is exiting 344 counties and three states for 2027 Medicare Advantage, as CMS premium pressure and rising costs force a retrenchment. This reduces future membership and revenue, weighing on the stock.

    This is a new negative development that could pressure the stock by limiting growth prospects.

July 2026
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

Q2 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

June 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.